Stroke

American Heart Association

American Stroke Association

Rapid Differential Endogenous Plasminogen Activator Expression After Acute Middle Cerebral Artery Occlusion

Naohisa Hosomi, Jacinta Lucero, Ji Hoe Heo, James A. Koziol, Brian R. Copeland and Gregory J. del Zoppo

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://stroke.ahajournals.org/content/32/6/1341

Rapid Differential Endogenous Plasminogen Activator Expression After Acute Middle Cerebral Artery Occlusion

Naohisa Hosomi, MD, PhD; Jacinta Lucero, BS; Ji Hoe Heo, MD, PhD; James A. Koziol, PhD;
Brian R. Copeland, MD; Gregory J. del Zoppo, MD

Background and Purpose—During focal cerebral ischemia, the microvascular matrix (ECM), which participates in microvascular integrity, is degraded and lost when neurons are injured. Loss of microvascular basal lamina antigens coincides with rapid expression of select matrix metalloproteinases (MMPs). Plasminogen activators (PAs) may also play a role in ECM degradation by the generation of plasmin or by MMP activation.

Methods—The endogenous expressions of tissue-type plasminogen activator (tPA), urokinase (uPA), and PA inhibitor-1 (PAI-1) were quantified in 10-μm frozen sections from ischemic and matched nonischemic basal ganglia and in the plasma of 34 male healthy nonhuman primates before and after middle cerebral artery occlusion (MCA:O).

Results—Within the ischemic basal ganglia, tissue uPA activity and antigen increased significantly within 1 hour after MCA:O ($2P<0.005$). tPA activity transiently decreased 2 hours after MCA:O ($2P=0.01$) in concert with an increase in PAI-1 antigen ($2P=0.001$) but otherwise did not change. The transient decrease in free tPA antigen was marked by an increase in the tPA–PAI-1 complex ($2P<0.001$). No significant relations to neuronal injury or intracerebral hemorrhage were discerned.

Conclusions—The rapid increase in endogenous PA activity is mainly due to significant increases in uPA, but not tPA, within the ischemic basal ganglia after MCA:O. This increase and an increase in PAI-1 coincided with latent MMP-2 generation and microvascular ECM degeneration but not neuronal injury. (***Stroke***. 2001;32:1341-1348.)

Key Words: basal ganglia ■ cerebral ischemia, focal ■ microcirculation ■ plasminogen activators ■ tissue plasminogen activator ■ baboons

Focal cerebral ischemia is responsible for a loss of microvascular integrity, manifested by increased endothelial cell permeability and loss of basal lamina matrix antigens.[1,2] After experimental middle cerebral artery (MCA) occlusion (MCA:O) and during reperfusion (MCA:O/R), the major basal lamina constituents, laminin, collagen IV, and cellular fibronectin, decrease roughly in parallel,[1] in association with microvascular hemorrhage.[2] Loss of basal laminal integrity coincides with a rapid increase in the expression of latent matrix metalloproteinase (MMP)-2 in the ischemic core (Ic) in a nonhuman primate MCA:O model.[3] Plasminogen activators (PAs) may also play several roles in cerebral ischemic injury to facilitate degradation of basal laminal ligands. Collagen, laminin, fibronectin, elastin, and/or myelin basic protein are degraded either directly by plasmin or by select activated MMPs requiring PA expression.[4–8] The disruption of normal cell-matrix adhesion has been associated with cell death,[9] edema,[10] loss of cell viability,[11] and hemorrhage[3] in several systems. Latent MMP-9 expression is associated with hemorrhagic transformation in the nonhuman primate, but the nature of its activation remains uncertain.[3] A contribution of plasmin, via PA generation, to pro-MMP-9 activation in the

ischemic parenchyma is a potential mechanism. Some or all of these PA-dependent effects could contribute to central nervous system (CNS) injury. However, during focal cerebral ischemia, the tissue-related contributions of PAs to cerebral vascular and neuronal injury and recovery processes have not been detailed.

PA activities have been described in the normal rodent brain.[12] Recent reports have indicated that tissue-type PA (tPA)[13] or urokinase (uPA)[14] may increase in the rodent brain after experimental MCA:O. Increased PA activity was detected within the caudate putamen after MCA:O in mice.[15] But, there has been considerable disagreement about the nature of the PA responses to MCA:O in rodents and their significance. Although uPA activity appears to be increased in several studies,[14,16] there is no agreement concerning the responses of tPA-like proteinase activity to MCA:O.[13,14,16,17] Wang et al[13] have suggested that increases in tPA-like proteinase activity may contribute to excitotoxic neuronal damage in mice. Therefore, the activation of the PA system during focal cerebral ischemia requires further scrutiny. Furthermore, the tissue content of the PAs and their principal inhibitor must be separated from the contributions of plasma.

Stroke is available at http://www.strokeaha.org

We hypothesized that the upregulation of tissue-related tPA and/or uPA must occur rapidly to initiate the loss in microvascular integrity[1] and accompany the changes in microvascular integrin receptor expression[18] and neuronal injury.[19] Increased PA expression would suggest a mechanism for pro-MMP-9 activation, whereas a linear association of increased PA expression with neuronal injury would tie the PA to neurodegeneration. We demonstrate rapid significant increases in uPA and PA inhibitor (PAI)-1, but not tPA, in the parenchyma of the ischemic basal ganglia very early after MCA:O. The sources of these PA-PAI axis components appear distinctly separate.

Materials and Methods

The experimental procedures used to obtain the tissues for the present study were approved by the institutional Animal Research Committee and were performed according to standards published by the National Research Council (*Guide for the Care and Use of Laboratory Animals*) and the US Department of Agriculture Animal Welfare Act. Every effort was made to ensure that the animals were free of pain and discomfort. All experiments and procedures were attended by at least 1 institutional veterinarian, members of the primate handling staff, research associates, and the principal investigator.

Experimental Stroke Model

Cerebral tissues from 34 adolescent male baboons (*Papio anubis/cynocephalus*) were used for the present study. The procedures for development of the MCA:O/R stroke model have been detailed in previous studies.[1,3,20] All animals were allowed a 7-day procedure-free interval after transorbital implantation of an eccentric balloon compression device around the proximal MCA. Twenty baboons underwent MCA:O for 1 hour (n=4), 2 hours (n=6), or 3 hours or MCA:O with subsequent reperfusion for 1 hour (n=4), 4 hours (n=3), or 24 hours (n=3). In addition, a group of baboons that did not undergo device implantation (n=6) and a group of baboons with lenticulostriatal territory injury harvested 7 days later (n=6) provided additional control materials. Two baboons who underwent only the implantation procedure served as sham-operated controls.

Tissue Processing and Sample Extracts

Experiments were terminated under thiopental Na$^+$ anesthesia by left ventricular transcardiac perfusion at 180 to 200 mm Hg with chilled perfusate containing heparin (200 IU/L), nitroprusside (1 mg/L), and BSA (50 g/L) (Sigma Chemical Co). The perfused brains were removed en bloc within 15 minutes of complete perfusion and were subdivided into 1-cm coronal slices. From each slice, symmetrically located blocks of both basal ganglia were cut and embedded in Tissue-Tek OCT (Miles Inc). Three consecutive 10-μm cryostat sections were minced and dissolved in 100 μL lysis buffer (50 mmol/L Tris-HCl [pH 7.5], 0.1 mol/L L-arginine, 150 mmol/L NaCl, 1.0% Triton X-100, 0.005% Brij 35, and 0.05% NaN$_3$) for 10 minutes and centrifuged at 4°C for 20 minutes at 9000 rpm. Supernatants were divided into aliquots and stored at −80°C. Preliminary experiments determined the optimal conditions for homogenization and activity extraction.

Blood Sampling

Blood samples were drawn from the peripheral vein into tubes containing heparin or EDTA at various times and centrifuged at 3000 rpm for 20 minutes, and the plasmas were stored at −80°C.

Protein Concentration

The protein contents of tissue and plasma samples were determined according to the Bradford method with BSA as the standard. MCA:O produced a significant reduction in protein content per unit volume in the ischemic basal ganglia ($2P<0.001$) (Figure 1), consistent with


Figure 1. Time course of protein content changes in ischemic and nonischemic basal ganglia after MCA:O.

previous findings.[21] All activity and antigen levels were normalized for protein content to the Ic (see below). After transcardiac perfusion, plasma protein (IgG) represented ≤0.007% of control basal ganglia.

Plasminogen-Gelatin Zymography

Plasminogen-gelatin zymography was performed by a modification of published methods.[3,22] The brain tissue and plasma samples (10 μg protein) were resolved under nonreducing conditions on 8% SDS-polyacrylamide gels containing 0.01 U/mL plasminogen and 1.5 mg/mL gelatin (Sigma). For standardization, 10 pg of human melanoma tPA (Sigma) and 10 pg of recombinant human uPA (a kind gift of Drs Andrew P. Mazar, Attenuon, San Diego, Calif, and Don Eisenhauer, Abbott Laboratories, Chicago, Ill) were loaded onto each gel. After electrophoresis, the gels were washed 3 times in 2.5% Triton X-100 solution and then incubated in 100 mmol/L Tris-HCl (pH 8.2) buffer for 18 hours at 37°C. The gels were stained with 0.1% amido black solution. On destaining, gelatinolytic activity was demonstrated as clear zones (Figure 2).

To confirm the nature of each band, plasminogen-containing gels were incubated with or without 10 mmol/L CaCl$_2$, 0.1 mmol/L amiloride, 2 mmol/L phenylmethylsulfonyl fluoride (Sigma), or 1 μmol/L trans-epoxysuccinyl-L-leucylamido-butane (E-64, Sigma). In addition, individual samples were incubated with function-blocking anti-human polyclonal antibodies against tPA (American Diagnostica, Inc), uPA (American Diagnostica, Inc), or PAI-1 (a kind gift of Dr David J. Loskutoff, The Scripps Research Institute, La Jolla, Calif) for 60 minutes at 37°C before application to the gel.

Immunoblotting

Samples (100 μg protein per lane) were separated under nonreducing conditions on 8% SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose membranes (Schleicher & Schuell Inc) by the semidry blotting method. Blocking with 5% nonfat milk in PBS containing 0.1% Tween 20 (PBST) was followed by incubation with the primary antibody for 1 hour at 37°C and with horseradish peroxidase-conjugated anti-rabbit or anti-goat IgG antibody (Santa Cruz Biotechnology Inc or Vector Laboratories, Inc) at 20°C for 1 hour. After each incubation, the blots were washed in PBST to remove unbound antibody. Bound antibody was detected by enhanced chemiluminescence (NEN Life Science Products Inc).

Goat anti-human melanoma tPA antibody (American Diagnostica, Inc), rabbit anti-human uPA antibody (Dr Andrew P. Mazar, Attenuon, San Diego, Calif), and rabbit anti-human PAI-1 antibody (Dr David J. Loskutoff, The Scripps Research Institute, La Jolla, Calif) were used as the primary antibodies for the respective immunoblot studies. Melanoma tPA, recombinant uPA, and recombinant PAI-1 (Dr David J. Loskutoff) served as controls. To prepare the control for the tPA–PAI-1 and uPA–PAI-1 bound forms, equal amounts of tPA or uPA and PAI-1 were incubated at 37°C for 10 minutes before application for electrophoresis. Goat or rabbit nonimmunized IgG was used as a primary antibody for the control. Absorption studies were performed by using a primary antibody incubated with melanoma tPA or recombinant uPA for 1 hour at 37°C.

Figure 2. Representative plasminogen-gelatin zymograms of the ischemic (R) and nonischemic (L) basal ganglia display clear evidence of uPA (54 kDa), tPA (61 kDa), and tPA–PAI-1 complex (105 kDa) activity. Sample incubation with respective antibodies (Abs) deleted the corresponding gelatinolytic band(s) (see text) (A). Also shown are time-course studies of PA activities from 3 animals each: no ischemic challenge (B), 2 hours after MCA:O (C), and 24-hour reperfusion after 3 hours of MCA:O (D). The uPA activity band, but not the tPA band, increased 2 hours after MCA:O.

Quantification of Immunoblotting and Zymography

Immunoblot films and zymography gels were scanned by using a Personal Densitometer SI (Molecular Dynamics Inc) under the mode of 12 bits per pixel digital resolution and 50-μm pixel size and quantified by NIH Image 1.61 on a Macintosh platform. Each measurement was calibrated with a step tablet (Kodak Scanner Step

Tablet, ST-34). The area under the densitometry curve is expressed as the integrated density (IDA).

Intragel and Intergel Reproducibility

Preliminary plasminogen zymography experiments with human melanoma tPA and recombinant human uPA (from 1 to 1000 pg) demonstrated that the technique could detect as little as 1 pg of each

**Figure 3.** Time course of changes in uPA activity (A) and antigen (B), tPA activity (C) and antigen (D), and PAI-1 antigen (E) in ischemic and nonischemic basal ganglia and plasma. At each time point, uPA activity and antigen and PAI-1 antigen increased within 1 hour after MCA:O in the ischemic basal ganglia. In contrast, tPA activity, but not antigen, decreased transiently at 2 hours after MCA:O.

PA. The log (integrated density) for each sample was linear with respect to the log (PA content) ($r=0.992$ and $2P<0.0001$ for tPA, $r=0.988$ and $2P<0.0001$ for uPA). The PA activities from both brain and plasma samples were all within that range. The intragel reproducibility for tPA and uPA were quite acceptable, with coefficients of variability of 2.3% (n=8) and 5.4% (n=8), respectively, by use of 10 pg of each PA. The intergel reproducibility of tPA and uPA was satisfactory, providing coefficients of variability of 11.7% and 11.0%, respectively (n=6 gels each).

dUTP Incorporation and Region of Cellular Injury

Evidence of nuclear DNA scission/repair was taken as an indication of significant cellular injury, as previously described.[19] Incorporation of digoxigenin-dUTP on 10-μm cryosections was detected by the DNA polymerase I–based procedure. The region containing cells with nuclear dUTP incorporation (dUTP$^+$) was defined as the Ic. All activities were normalized for the Ic region. The validity of this approach was confirmed by immunohistochemistry of adjacent sections (D.-I. Chang, G.J. del Zoppo, unpublished data, 2001). The absolute numbers and densities of total dUTP$^+$ cells and dUTP$^+$ neurons were determined within a 1.5-mm^2 region of interest centered within the Ic by computer-assisted quantitative video-imaging microscopy.

Enzyme-Linked Immunosorbent Assays

tPA, uPA, and PAI-1 antigen contents in brain tissue extract and plasma were determined by a commercially available ELISA kit (American Diagnostica Inc). Assays were performed according to the manufacturer's instructions. Antigen concentrations were calculated in nanograms per milligram protein.

Analysis of Data

All data are presented as mean±SD. Differences in the time courses of molecules between ischemic and matched nonischemic brain samples were assessed by using 2-way ANOVA, with Bonferroni corrections for multiple comparisons. One-way ANOVA was used for comparison between ischemic and nonischemic animals or between hemorrhagic and nonhemorrhagic animals. Associations between PA (activity and antigen) and ischemic injury were performed by means of linear regression. Jackknifed standard errors (SEs) of reported correlation coefficients are provided for assessment of the precision of the estimated correlations. Significance was set at $2P<0.05$.

Results

Zymographic Characterization of uPA, tPA, and PAI-1 Expression

Plasminogen-gelatin zymographic studies displayed clear evidence of tPA and uPA activity within 10-μm frozen sections from both ischemic and nonischemic basal ganglia (Figure 2). Three bands (105, 61, and 54 kDa) were identified in all plasma-free brain tissue extracts, and 2 bands (105 and 54 kDa) were identified in all plasma samples, which were inhibited by phenylmethylsulfonyl fluoride but not the cysteine protease inhibitor E-64. No proteolytic bands were seen in the plasminogen-free gel whether or not the incubation buffer contained CaCl$_2$. These findings confirmed that the gelatinolytic activities were serine proteases that cleave plasminogen to plasmin and were not MMPs. Plasmin activity was not detectable with plasminogen-free zymography. The 2 proteolytic bands of 61 and 105 kDa were inhibited by a function-blocking antibody against human tPA. The 105-kDa band was also inhibited by the anti–PAI-1 antibody, identifying it with the tPA–PAI-1 complex. The single


Figure 4. Comparison of uPA antigen and activity, tPA antigen and activity, and PAI-1 antigen between animals with and without ischemic injury. uPA activity and antigen and PAI-1 antigen were significantly greater in the Ic region of the animals undergoing MCA:O than in those without ischemic injury. Symbols represent individual animals from each time point. *$2P<0.01$ vs nonischemic basal ganglia.

proteolytic band of 54 kDa was inhibited by amiloride and by the function-blocking antibody against human uPA.

uPA Expression During MCA:O

Parenchymal uPA activity and antigen increased significantly within 1 to 2 hours after MCA:O in the ischemic basal ganglia ($2P<0.005$) (Figures 2, 3A, and 3B). Both uPA activity and antigen were significantly greater in the Ic regions than in identical nonischemic tissues ($2P<0.001$) (Figure 4). No difference in uPA activity or antigen was observed between the sham-operated and control animals.

In the plasma, uPA activity, but not antigen, demonstrated a small but significant increase early after MCA:O ($2P<0.05$) (Figure 3A and 3B). Plasma uPA antigen content did not change appreciably over the time from MCA:O.

tPA and PAI-1 Expression During MCA:O

A significant increase in PAI-1 antigen ($2P=0.001$) and a decrease in free tPA activity ($2P=0.01$) were seen by 2 hours after MCA:O in the ischemic basal ganglia compared with the nonischemic regions (Figure 3C and 3E). A transient increase in the tPA–PAI-1 complex and a coordinate decrease in unbound tPA at 2 hours after MCA:O ($2P<0.001$) explained these changes in the ischemic tissue (Figure 5). Total paren-

Figure 5. Immunoblot study of tPA and PAI-1 antigens in ischemic and nonischemic basal ganglia (see Figure 2). Total tPA antigen remained unchanged, but a significant reduction in free tPA, equivalent to the formation of detectable tPA–PAI-1 complex, was seen 2 hours after MCA:O in the ischemic basal ganglia. L represents the nonischemic basal ganglia. R represents the ischemic basal ganglia.

chymal tPA antigen content remained unchanged throughout MCA:O/R (Figure 3D), and both tPA antigen and activity in the Ic region were not different in control and sham-operated animals ($2P=0.55$) (Figure 4). But PAI-1 antigen in the Ic region in all ischemic animals increased significantly ($2P<0.003$).

In plasma, only the gelatinolytic activity of the tPA–PAI-1 complex was detected. Plasma PAI-1 antigen increased significantly ($2P<0.05$) after MCA:O, in parallel with the increase in PAI-1 antigen in the ischemic basal ganglia (Figure 3E).

PA Expression and Neuronal Injury

The relations of uPA activity/antigen, tPA activity/antigen, and PAI-I antigen content to the density of dUTP$^+$ cells and neurons at 2-hour MCA:O were examined.[3,19] No significant linear relationship between the contents of each PA or PAI and the density (number per unit area) of dUTP$^+$ neurons was observed: uPA activity/antigen=($r=0.739$, SE=0.257, $2P=0.093$)/($r=0.803$, SE=0.242, $2P=0.054$); tPA activity/antigen=($r=0.218$, SE=0.539, $2P=0.678$)/($r=0.286$, SE=0.257, $2P=0.583$); and PAI-1 antigen=($r=0.687$, SE=0.232, $2P=0.132$). However, a weak association with uPA content might exist. This is because of the large SE in the uPA relationships.


Figure 6. Comparison of uPA, tPA, and PAI-1 antigens between the ischemic animals with or without hemorrhagic transformation. For uPA and PAI-1, compared with control animals, animals undergoing MCA:O displayed significantly greater antigen levels whether they presented hemorrhagic transformation or not. No difference in tPA antigen levels was observed between the normal control and MCA:O animals. Symbols represent individual animals from each time point. *$2P<0.01$ vs nonischemic basal ganglia.

Association of PAs With Hemorrhagic Transformation

At least 1 animal at each time point, 15 in total (44.1%), demonstrated visible evidence of hemorrhagic transformation within the Ic region after MCA:O. No significant differences in tPA, uPA, and PAI-1 contents between the animals that displayed hemorrhagic transformation and those without hemorrhagic transformation after MCA:O were detected (Figure 6).

Discussion

Plasmin, in addition to dissolving fibrin-containing thrombi and fibrinogen, is capable of degrading selected matrix proteins of the basal lamina, elastin, and myelin basic protein either directly or through the activation of select latent MMPs.[4–8] The ability of PAs to alter microvascular matrix integrity in response to focal cerebral ischemia has so far not been clearly defined.[13,14,23] The initial step is to examine the effect of MCA:O on the PA/PAI axis within the brain parenchyma. From these experiments and those of others,[12]

there appears to be no zymographic evidence of free plasmin in normal brain tissue. We demonstrate an immediate significant increase in gelatin-proteolytic activity after MCA:O that was mainly due to significant increases in uPA within the ischemic basal ganglia. Parallel increases in PAI-1 were reflected by an increase in tPA–PAI-1 complex formation and a transient decrease in tPA activity in the same territory. uPA antigen and activity and tPA-associated PAI-1 antigen (assigned to the Ic region) increased significantly during focal cerebral ischemia compared with no ischemic injury. However, no relation to neuronal injury was evident. Furthermore, there was no significant difference among the animals that displayed hemorrhagic transformation and those without hemorrhagic transformation with respect to uPA and tPA/PAI-1.

The extracellular matrix provides a substructure for the endothelial cell and astrocyte components of the cerebral microvasculature, contributing a second element of the blood-brain barrier. Intact microvascular basal lamina and integrin-mediated matrix adhesion are required for cell survival.[9,11] Focal cerebral ischemia degrades microvascular integrity through major alterations in endothelial cell permeability and loss of the vascular matrix.[2] The major basal lamina constituents, including laminin-1, laminin-5, collagen IV, and cellular fibronectin, decrease roughly in parallel during MCA:O/R.[1,18] That loss is associated with microvascular hemorrhage.[2] From parallel studies, loss of basal laminal integrity and neuronal injury are accompanied by a rapid simultaneous increase in tissue expression of uPA and latent MMP-2, but not tPA, in this model.[3,19] PAs may facilitate degradation of basal lamina via several pathways. Plasmin and uPA, but not tPA, can activate latent MMP-1, MMP-3, and MMP-9, or in the case of pro-MMP-2, activation is through the proteolytic activation of membrane type-1–MMP.[4,8,24–26] Some or all of these PA-dependent effects can contribute to postischemic CNS injury.

With a modification of zymography with the use of gelatin (collagen) as the plasmin substrate, tPA and uPA activities from 10-μm frozen sections were readily detectable and reproducible. Within nonischemic basal ganglia, tPA activity (calculated from the normalized integrated densities) was $\approx$67% of uPA activity in control animals, although tPA antigen content was 33 times that of uPA antigen. When casein was used as the substrate for zymography, tPA activity was $\approx$156% of uPA activity in control animals. These differences may reflect the separate requirements for plasmin formation by tPA and uPA activity with gelatin as the substrate, the known contributions of fibrin to optimal in vivo plasminogen activation by tPA,[27] or other aspects of the activation of plasminogen by tPA. Nonetheless, the simple extraction procedure used in the present study released nearly all uPA and tPA antigen/activity into the soluble phase (96.8%/96.5% and 97.3%/97.4% [n=6], respectively). The specific activities of uPA or tPA were similar in the soluble and the nonsoluble phases (data not shown). The low tPA specific activity, compared with uPA specific activity, is not readily explained by inhibition with PAI-1, because the tPA–PAI-1 complex levels in nonischemic tissue were low. Importantly, although the activity assays attempt to detect matrix-relevant PA activities, the true condition within cerebral tissue is unknown.

Rosenberg et al[14] first described increased uPA-like and decreased tPA-like proteinase activities by 12 to 24 hours after permanent MCA:O in Wistar-Kyoto rats and SHR, whereas Ahn et al[16] noted an increase in uPA-like proteinase activity and no change in tPA-like proteinase activity in C57BL/6J mice.[16] Wang et al[13] suggested that increases in tPA-like proteinase activity after MCA:O contribute to neurodegeneration. tPA, but not uPA, was assigned a role in neuronal injury within the murine hippocampus.[13,28] The appearance of both PAs in neuronal cells has been reviewed recently.[29] Pfefferkorn et al[15] also observed increased PA activity within the caudate putamen by 9 hours after MCA:O in Wistar rats, although the PA was not defined. PAI-1 antigen was apparently increased 4 hours after MCA:O in Wistar rats,[30] but no relation of PAI-1 to uPA and tPA activity has been reported. The very rapid (1-hour) increase in uPA, the increase in the tPA–PAI-1 complex, and the transient decrease in free tPA are consistent findings matching the rapid appearance of other gene products in the microvasculature after MCA:O in the nonhuman primate.[17,31–33] Differences in the species and models used, ancillary effects of the anesthetics in the rodent studies, retained plasma, the use of the more sensitive zymographic assays in the present experiments, and other technical differences may also contribute to the discrepant findings. In recent studies, we have shown that residual plasma significantly decreases the activity of tPA and uPA in rodent brain tissue samples (G.J. del Zoppo, E. Lo, M. Asahi, S.E. Baer, unpublished data, 2000).[19]

uPA synthesis has been attributed to a number of CNS cell types, including endothelial cells, neurons, astrocytes, and microglia in vivo or in vitro.[29,33–36] Given the rapid and persistent elevation of uPA in the ischemic basal ganglia, it is unlikely that uPA is derived from the plasma compartment. If only a contribution of edema to the tissue content of plasma and stable plasma uPA content are assumed, a mechanism to concentrate uPA 40-fold from plasma would be required to explain the early tissue increase in uPA content.

In contrast, the PAI-1 content of ischemic tissue and plasma increased in parallel, suggesting that plasma PAI-1 entered the edema fluid directly as early as 1 to 2 hours after MCA:O. Although PAI-1 synthesis has been attributed to endothelial cells, neurons, and astrocytes,[32,37,38] any in situ production by normal brain tissue might be overwhelmed by plasma PAI-1. Given the parallel increases in tissue and plasma PAI-1, it is likely that a common source of the inhibitor is the endothelium. Increased PAI-1 mRNA and PAI-1 immunoreactive microvessels have been detected 4 hours after MCA:O in Wistar rats.[30] Docagne et al[17] observed that PAI-1, but not tPA, mRNA expression was increased between 24 hours and 3 days after MCA:O in mice.

In the ischemic basal ganglia, total tPA antigen did not change, although free tPA activity decreased transiently. The early decrease in tPA activity is explained by formation of the tPA–PAI-1 complex. tPA, uPA, and PAI-1 secretion have been attributed variously to stimulated endothelial cells, neurons, astrocytes, or microglia in vivo or in vitro,[32–38] but tPA antigen and activity did not accumulate in the ischemic

tissue in the present study. In the nonischemic brain, tPA antigen is localized to selected noncapillary microvessels.[39] The differential expression of tPA relative to uPA and PAI-1 might be explained by early stimulation of uPA and PAI-1 generation by tumor necrosis factor-α and -β, transforming growth factor-β, and interleukin-1β (all inflammatory cytokines), which do not stimulate endothelial cell tPA synthesis and secretion.[17,32,33] Expression of these cytokines increases early within the ischemic zone in rodents after MCA:O.[40,41] With human microvascular endothelial cells, epidermal growth factor increases the synthesis and secretion of tPA, which is inhibited by tumor necrosis factor-α.[42] Therefore, microvascular endothelium may be responsible for the increased uPA and PAI-1 antigen, but not tPA antigen.

Recent reports have suggested that tPA might promote neurodegeneration within the rat hippocampus by alteration in laminin integrity.[13,43] However, there was no firm relation of uPA, tPA, and PAI-I content to neuronal injury in the ischemic basal ganglia by 2 hours of MCA:O in the present study. This differs from the significant linear relationship of pro-MMP-2 content to neuronal injury in the same setting.[3] Recent reports comparing uPA$^{(-/-)}$, tPA$^{(-/-)}$, PAI-1$^{(-/-)}$, plasminogen $^{(-/-)}$, and wild-type mice suggest that the absence of tPA, but not uPA, decreased the apparent volume of ischemic injury.[23] Furthermore, plasminogen $^{(-/-)}$ constructs had increased regions of ischemic injury. Those experiments do not address the acute condition and are subject to other concerns noted for selected well-characterized knockout and transgenic mouse preparations subject to MCA:O.[23,44–46] Despite the lack of change in total tPA antigen, it cannot be excluded that tPA increases in microscopically localized areas and contributes to neuronal injury.

Although no direct association of uPA with hemorrhagic transformation was observed in the present study (Figure 6), increased uPA in the ischemic zones of all animals could promote the activation of pro-MMP-9, which is associated with hemorrhagic transformation in this model. At the clinical level, it seems likely that interventional treatment with exogenous PAs could further increase the risk of hemorrhagic transformation if endogenous uPA is already increased. This argument assumes that the extravasation of blood is not itself the source of the increased pro-MMP-9.

The significant increase in uPA within the ischemic basal ganglia coincides with pro-MMP-2 generation and microvascular matrix degeneration, but not neuronal injury, after MCA:O. Despite the rapid and persistent increase in gelatin-proteolytic activity mainly due to significantly increased uPA and the decreased tPA activity 2 hours after MCA:O, the actual compartmentalization of the endogenous PAs in the CNS and their individual effects on microvascular matrix, neuronal integrity, and clinical outcome remain to be defined.

Acknowledgments

References

1. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. *Stroke*. 1995;26:2120–2126.
2. Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. *J Cereb Blood Flow Metab*. 1996;16:1373–1378.
3. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. *J Cereb Blood Flow Metab*. 1999;19:624–633.
4. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. *Cancer Res*. 1990;50:5997–6001.
5. Norton WT, Cammer W, Bloom BR, Gordon S. Neutral proteinases secreted by macrophages degrade basic protein: a possible mechanism of inflammatory demyelination. *Adv Exp Med Biol*. 1978;100:365–381.
6. McGuire PG, Seeds NW. The interaction of plasminogen activator with a reconstituted basement membrane matrix and extracellular macromolecules produced by cultured epithelial cells. *J Cell Biochem*. 1989;40:215–227.
7. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. *Annu Rev Cell Biol*. 1988;4:93–126.
8. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. *J Clin Invest*. 1991;88:1067–1072.
9. Frisch SM, Francis H. Disruption of epithelial cell-matrix interaction induces apoptosis. *J Cell Biol*. 1994;124:619–626.
10. Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. *Neurology*. 1997;48:921–926.
11. Re F, Zanetti A, Sironi M, Polentarutti N, Lanfrancone L, Dejana E, Colotta F. Inhibition of anchorage-dependent cell spreadings triggers apoptosis in cultured human endothelial cells. *J Cell Biol*. 1994;127:537–546.
12. Sappino A-P, Madani R, Huarte J, Belin D, Kiss JZ, Wohlwend A, Vassalli J-D. Extracellular proteolysis in the adult murine brain. *J Clin Invest*. 1993;92:679–685.
13. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. *Nat Med*. 1998;4:228–231.
14. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. *J Cereb Blood Flow Metab*. 1996;16:360–366.
15. Pfefferkorn T, Staufer B, Liebetrau M, Bultemeier G, Vosko MR, Zimmermann C, Hamann GF. Plasminogen activation in focal cerebral ischemia and reperfusion. *J Cereb Blood Flow Metab*. 2000;20:337–342.
16. Ahn MY, Zhang ZG, Tsang W, Chopp M. Endogenous plasminogen activator expression after embolic focal cerebral ischemia in mice. *Brain Res*. 1999;837:169–176.
17. Docagne F, Nicole O, Marti HH, MacKenzie ET, Buisson A, Vivien D. Transforming growth factor-b1 as a regulator of the serpins/t-PA axis in cerebral ischemia. *FASEB J*. 1999;13:1315–1324.
18. Wagner S, Tagaya M, Koziol JA, Quaranta V, del Zoppo GJ. Rapid disruption of an astrocyte interaction with the extracellular matrix mediated by integrin $\alpha_{6\beta4}$ during focal cerebral ischemia/reperfusion. *Stroke*. 1997;28:858–865.
19. Tagaya M, Liu K-F, Copeland B, Seiffert D, Engler R, Garcia JH, del Zoppo GJ. DNA scission after focal brain ischemia: temporal differences in two species. *Stroke*. 1997;28:1245–1254.
20. del Zoppo GJ, Copeland BR, Harker LA, Waltz TA, Zyroff J, Hanson SR, Battenberg E. Experimental acute thrombotic stroke in baboons. *Stroke*. 1986;17:1254–1265.
21. Bell BA, Symon L, Branston NM. CBF and time thresholds for the formation of ischemic cerebral edema, and effect of reperfusion in baboons. *J Neurosurg*. 1985;62:31–41.
22. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrate. *Anal Biochem*. 1980;102:196–202.
23. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. *Circulation*. 1999;99:2440–2444.
24. Kazes I, Delarue F, Hagege J, Bouzhir-Sima L, Rondeau E, Sraer JD, Nguyen G. Soluble latent membrane-type 1 matrix metalloprotease

secreted by human mesangial cells is activated by urokinase. *Kidney Int*. 1998;54:1976–1984.

25. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. *Proc Natl Acad Sci U S A*. 1989;86: 2632–2636.

26. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. *EMBO J*. 1997;16:2319–2332.

27. Collen D, Lijnen HR, Bulens F, Vandamme AM, Tulinsky A, Nelles L. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains. *J Biol Chem*. 1990;265:12184–12191.

28. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. *J Neurosci*. 1997;17:543–552.

29. Vivien D, Buisson A. Serine protease inhibitors: novel therapeutic targets for stroke? *J Cereb Blood Flow Metab*. 2000;20:755–764.

30. Zhang GZ, Chopp M, Goussev A, Lu D, Morris D, Tsang W, Powers C, Ho K-L. Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. *J Neurosci*. 1999;19:10898–10907.

31. Abumiya T, Lucero J, Heo JH, Tagaya M, Koziol JA, Copeland BR, del Zoppo GJ. Activated microvessels express vascular endothelial growth factor and integrin $\alpha_{v\beta3}$ during focal cerebral ischemia. *J Cereb Blood Flow Metab*. 1999;19:1038–1050.

32. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium: effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. *J Biol Chem*. 1988;263:5797–5803.

33. van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. *Blood*. 1990;75:1991–1998.

34. Masos T, Miskin R. Localization of urokinase-type plasminogen activator mRNA in the adult mouse brain. *Brain Res Mol Brain Res*. 1996;35: 139–148.

35. Tranque P, Naftolin F, Robbins R. Differential regulation of astrocyte plasminogen activators by insulin-like growth factor-I and epidermal growth factor. *Endocrinology*. 1994;134:2606–2613.

36. Nakajima K, Tsuzaki N, Shimojo M, Hamanoue M, Kohsaka S. Microglia isolated from rat brain secrete a urokinase-type plasminogen activator. *Brain Res*. 1992;577:285–292.

37. Patterson PH. On the role of proteases, their inhibitors and the extracellular matrix in promoting neurite outgrowth. *J Physiol (Paris)*. 1985; 80:207–211.

38. Vincent VA, Lowik CW, Verheijen JH, de Bart AC, Tilders FJ, Van Dam AM. Role of astrocyte-derived tissue-type plasminogen activator in the regulation of endotoxin-stimulated nitric oxide production by microglial cells. *Glia*. 1998;22:130–137.

39. Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. *Am J Pathol*. 1994;144: 855–861.

40. Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC, Feuerstein GZ. Tumor necrosis factor-α expression in ischemic neurons. *Stroke*. 1994;25:1481–1488.

41. Davies CA, Loddick SA, Toulmond S, Stroemer RP, Hunt J, Rothwell NJ. The progression and topographic distribution of interleukin-1β expression after permanent middle cerebral artery occlusion in the rat. *J Cereb Blood Flow Metab*. 1999;19:87–98.

42. Mawatari M, Okamura K, Matsuda T, Hamanaka R, Mizoguchi H, Higashio K, Kohno K, Kuwano M. Tumor necrosis factor and epidermal growth factor modulate migration of human microvascular endothelial cells and production of tissue-type plasminogen activator and its inhibitor. *Exp Cell Res*. 1991;192:574–580.

43. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. *Cell*. 1997;91:917–925.

44. Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz MA. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. *J Cereb Blood Flow Metab*. 1996;16: 981–987.

45. Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. *J Neurosci*. 1997;17:7655–7661.

46. Maeda K, Hata R, Bader M, Walther T, Hossmann KA. Larger anastomoses in angiotensinogen-knockout mice attenuate early metabolic disturbances after middle cerebral artery occlusion. *J Cereb Blood Flow Metab*. 1999;19:1092–1098.